Doxorubicin in lymphoma: Association between pharmacokinetic variability and clinical response

Avishay Elis, Michael Lishner, Scott Walker, Dina Atias, Avraham Korenberg, Gideon Koren

Research output: Contribution to journalArticlepeer-review

12 Scopus citations


Despite many years of clinical use in Hodgkin lymphoma, no previous studies have evaluated the relationship between doxorubicin pharmacokinetics and clinical response. In a pilot study, we associated the area under the curve of doxorubicin with successful remission. Patients with successful remission (n = 14) had a trend toward a higher median area under the curve than those who failed remission (n = 4; 36,390 versus 19,350 ng/mL × minute, P = 0.08, respectively). Median peak serum concentrations were 73 ng/mL among failures and 280 ng/mL in those who achieved remission (P = 0.06). The 2 groups did not differ regarding demographic and clinical parameters or doxorubicin dose. If corroborated by further studies, therapeutic drug monitoring of doxorubicin may be warranted in patients with Hodgkin lymphoma.

Original languageEnglish
Pages (from-to)50-52
Number of pages3
JournalTherapeutic Drug Monitoring
Issue number1
StatePublished - Feb 2010
Externally publishedYes


  • Clinical response
  • Doxorubicin
  • Hodgkin lymphoma
  • Pharmacokinetics
  • Therapeutic drug monitoring


Dive into the research topics of 'Doxorubicin in lymphoma: Association between pharmacokinetic variability and clinical response'. Together they form a unique fingerprint.

Cite this